- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00305019
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus
Studie Overzicht
Studietype
Inschrijving
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Guro-ku, Seoul
-
Guro-dong, Guro-ku, Seoul, Korea, republiek van, 152-703
- Korea University Guro Hospital
-
-
Jongno-Gu, Seoul
-
Yeongeon-dong, Jongno-Gu, Seoul, Korea, republiek van, 110-744
- Seoul National University
-
-
Kangdong-Gu, Seoul
-
Gil-dong, Kangdong-Gu, Seoul, Korea, republiek van, 134-701
- Kangdong Sacred Heart Hospital
-
-
Kangnam-Gu, Seoul
-
Dogok-dong, Kangnam-Gu, Seoul, Korea, republiek van, 146-92
- Yongdong Severance Hospital
-
Ilwon-dong, Kangnam-Gu, Seoul, Korea, republiek van, 135-710
- Samsung Medical Center
-
-
Songpa-Gu, Seoul
-
Pungnab2-dong, Songpa-Gu, Seoul, Korea, republiek van, 388-1
- Asan Medical Center
-
-
Yangchon-Gu, Seoul
-
Mok-dong, Yangchon-Gu, Seoul, Korea, republiek van, 911-1
- Ewha Womans University Hospital
-
-
Yougdungpo-Gu, Seoul
-
Youido, Yougdungpo-Gu, Seoul, Korea, republiek van, 150-713
- St. Mary's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patient who is between 18 and 60 years of age, inclusive
- Patient who is HBV DNA positive with DNA levels at screening more than 3 x 10^6 copies/mL.
Patient who is documented to be hepatitis B surface antigen (HBsAg) positive for > 6 months. Patient is HBeAg positive and anti-HBe negative.
Evidence of HBsAg (+) for the previous 6 months may include the following:
- documentation of HBsAg (+) for the previous 6 months
- documentation of HBsAg (+) for the previous 3 months and IgM anti-HBc negative at screening
- IgM anti-HBc negative and IgG anti-HBc positive at screening
- Patient who has ALT levels which are in the range of more than 2 to less than 10 times the upper limit of normal (x ULN) and bilirubin levels < 1.5 x ULN.
- Female patient with a negative serum (HCG) pregnancy test taken within 14 days of starting therapy.
- Patient who is able to give written informed consent prior to study start and to comply with the study requirements.
Patients who continue to meet the following criteria after completion of the Week 36 visit will have additional follow-up visits at Week 40, 44, 48:
- have received no additional therapy since completion of 12 weeks of treatment of L-FMAU and
- continue with period 1 log10 decrease in HBV DNA from baseline.
Exclusion Criteria:
- Patient who is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
- Patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for HBV infection.
- Patients with previous treatment with interferon that have ended less than 6 months prior to the screening visit.
- Patient who has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- Patient who is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV.
- Patient with clinical evidence of cirrhosis or hepatocellular carcinoma
- Patient who is pregnant or breast-feeding.
- Patient who is unwilling to use an "effective" method of contraception during the study and for up to 30 days after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., intrauterine device [IUD], barrier methods with spermicide or abstinence)
- Patient who has a clinically relevant history of abuse of alcohol or drugs.
- Patient who has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
- Patient who has creatinine clearance less than 60 mL/min as estimated by the following formula:
(140-age in years) (body weight [kg])/ (72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
Patients found to have tyrosine, methionine, aspartate, aspartate (YMDD) HBV DNA polymerase mutation after the enrollment will be excluded from the efficacy evaluation but included in the safety evaluation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
Werkzaamheid: verandering ten opzichte van baseline in HBV DNA (log10)
|
Secundaire uitkomstmaten
Uitkomstmaat |
---|
Veiligheid
|
Vitale functies
|
Bijwerkingen
|
Laboratorium testen
|
Efficacy: Proportion of patients with HBV DNA below 1 pg/mL
|
Proportion of patients with HBV DNA below the assay limit of detection (LOD) (SuperDigene HC test II LOD, <4,700 copies/mL)
|
Proportion of patients with hepatitis Be antigen (HBeAg) loss
|
Seroconversion rate (HBeAg loss and hepatitis Be antibody [HBeAb] positivity)
|
Biochemical improvement (e.g., ALT normalization)
|
Electrocardiogram (ECG)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Lever Ziekten
- Hepatitis, viraal, menselijk
- Hepadnaviridae-infecties
- DNA-virusinfecties
- Enterovirusinfecties
- Picornaviridae-infecties
- Hepatitis B
- Hepatitis
- Hepatitis A
- Anti-infectieuze middelen
- Antivirale middelen
- Clevudine
Andere studie-ID-nummers
- L-FMAU-201
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatitis B
-
Brii Biosciences LimitedVir Biotechnology, Inc.Actief, niet wervendChronische hepatitis B-virusinfectieSingapore, Thailand, Australië, China, Korea, republiek van
-
Mahidol UniversityOnbekendChronische hepatitis B, HBsAg, hepatitis B-vaccinThailand
-
Tasly Tianjin Biopharmaceutical Co., Ltd.Onbekend
-
Zhongshan Hospital Xiamen UniversityOnbekendGezond | Chronische hepatitis B-infectieChina
-
Tasly Tianjin Biopharmaceutical Co., Ltd.VoltooidHepatitis B-virus (HBV)China
-
University Hospital, Strasbourg, FranceWerving
-
Bristol-Myers SquibbVoltooidChronisch hepatitis B-virus, pediatrischVerenigde Staten, Korea, republiek van, Taiwan, Verenigd Koninkrijk, België, Canada, Russische Federatie, Argentinië, Duitsland, Griekenland, Indië, Israël, Polen, Roemenië
-
National Taiwan University HospitalPharmaEssentiaWervingChronische hepatitis B-virusinfectieTaiwan
-
Hannover Medical SchoolGerman Center for Infection ResearchWerving
-
Bristol-Myers SquibbVoltooidChronisch hepatitis B-virus